Eduardo Terán, GI Medical Oncologist at Vall d’Hebron Barcelona Hospital, posted on X:
“Disappointing results from the Phase 2 INNOVATION trial, maybe FLOT-T is a well tolerated option to improve tumor downsizing for surgery…
Brilliant discussion by Dr. Yoon on pCR and HER2 challenges in resectable GEA.”
